L-Cart Injection contains Levo-carnitine 1000 mg per dose, a naturally occurring amino acid derivative essential for the transport of long-chain fatty acids into the mitochondria for beta-oxidation and energy production. This injectable formulation is indicated for the treatment of primary and secondary carnitine deficiency, which may arise from genetic disorders, chronic renal failure, hemodialysis, or other metabolic conditions. L-Cart Injection is utilized to restore normal carnitine levels, thereby improving metabolic function and reducing symptoms such as muscle weakness, fatigue, and cardiomyopathy associated with carnitine deficiency. The administration of Levo-carnitine via injection ensures rapid bioavailability and is particularly beneficial in patients who are unable to tolerate oral supplementation or require immediate correction of deficiency. Dosage and duration of therapy should be individualized based on clinical response and laboratory parameters. Common adverse effects are generally mild and may include injection site reactions, nausea, or gastrointestinal discomfort. Caution is advised in patients with seizure disorders, as Levo-carnitine may lower the seizure threshold. L-Cart Injection should be used under medical supervision with appropriate monitoring to optimize therapeutic outcomes and minimize potential risks.